INTRODUCTION
Ebola virus (EBOV), a member of the family Filoviridae, is a single-stranded, negative-sense RNA virus that can cause acute hemorrhagic fever and rapid death within 7-14 days following infection in humans and nonhuman primates (Hoenen et al., 2006) . There are at least five different species of EBOVZaire, Sudan, Ivory Coast, Reston, and the recently identified Bundibugyo virus (Towner et al., 2008 )-having different patterns of pathogenicity in nonhuman primates and man (for example, EBOV-Reston causes no disease in man, whereas EBOV-Zaire is highly lethal). Several animal models have been developed to study the pathogenesis of filoviruses, including mouse, guinea pig, hamster and nonhuman primate models (Bowen et al., 1978; Bray et al., 1998; Connolly et al., 1999; Ryabchikova et al., 1996) . Adult mice are resistant to naturally occurring isolates of EBOV. However, a mouse-adapted variant of the Ebola Zaire virus is lethal when injected via the intraperitoneal route of infection, but not other routes (Bray et al., 1998) . The natural reservoir of EBOV is unknown, but it is clear that the infection of nonhuman primates and humans is an accidental dead-end event and that none of the physiologic abnormalities that occur during its course are the result of evolutionary adaptation of the virus to humans (Warfield et al., 2009 ). The resistance of other species such as rodents may allow for determination of the differences in the susceptibility between different accidental hosts. The interaction between the virus and immune cells plays a critical role in the pathogenesis of this disease. During the early stage of infection, the virus infects cells of the monocytic lineage, including dendritic cells (DCs), monocytes, and macrophages, whereupon these cells die or become nonfunctional and lose their ability to stimulate antigen-specific T cells (Mohamadzadeh et al., 2007) . As the disease progresses, there is increased release of proinflammatory cytokines, lymphocyte apoptosis, and spread of the virus to nonlymphocytic cell types such as hepatocytes (Mohamadzadeh, 2009; Mohamadzadeh et al., 2007) . Thus, multiple mechanisms have been shown to contribute to EBOV pathogenesis.
Protein tyrosine phosphatases (PTPs) are critical regulators of signal transduction and include a set of 107 genes within the human genome (Alonso et al., 2004) . Among these is CD45, an abundant protein expressed in nucleated cells of hematopoietic origin (Thomas, 1989) . The primary role of CD45 is regulation of antigen-receptor signaling of T and B cells via dephosphorylation of the Src family kinases (SFKs) (Alexander, 2000; Hermiston et al., 2003; Thomas and Brown, 1999) . CD45 can act both as a positive and negative regulator of SFKs, depending on the nature of the stimulus, the cell type involved, and the developmental stage of the cells (Alexander, 2000; Hermiston et al., 2003; Thomas and Brown, 1999) . In addition to its role in regulating intracellular signaling, CD45 is thought to play a role in mediating cell-cell contact by modulating integrin-mediated adhesion (Roach et al., 1997) . Thus, CD45 is a pleiotropic mediator of lymphocyte function.
We recently observed that mice expressing intermediate levels of CD45 were protected against the highly virulent Ames strain of B. anthracis, a gram-positive spore-forming bacterium (Panchal et al., 2009 ). To explore the beneficial effects of modulating CD45 levels in other disease models and to investigate whether evolutionarily distinct pathogens share a convergent host pathway that could serve as a common therapeutic target, mice expressing differential levels of CD45 were challenged with EBOV. In this study, we show that reduced CD45 expression levels protect mice from the lethal effects of EBOV infection. Mechanistic studies of mice challenged with EBOV revealed that reduced CD45 expression levels retained the ability to properly regulate early gene expression and inflammation, as well as generated a robust protective immunity response. All of these concerted changes contributed to reduced apoptosis and rapid viral clearance, leading to the survival of the mice.
RESULTS

Mice Expressing Reduced CD45 Levels Survive Ebola Challenge
The pathogenesis of the mouse-adapted EBOV-Zaire infections in mice largely resembles that in guinea pigs and nonhuman primates (Bradfute et al., 2007 (Bradfute et al., , 2008 Bray et al., 1998) , although subtle differences in coagulopathy have also been observed (Gibb et al., 2001) . Therefore, to explore the role of reduced CD45 expression in EBOV pathogenesis, we utilized mice engineered to express a range of CD45 levels (11%, 22%, 36%, 62%, and 77% of the wild-type level) and mice with a point mutation C817S, inactivating CD45 phosphatase activity but expressing 62% (CSV10 +/À ) or 100% (CSV10 +/+ ) of the wild-type CD45 protein, were utilized (Table 1) . These cell-surface CD45 expression levels were determined by flow cytometry using erythrocyte-depleted blood cells ( Figure 1A ) and based on comparison of mean fluorescence intensity with wild-type controls. The different mice groups were challenged with > 3000 LDB 50B of mouse-adapted EBOV. Mice expressing 11%-77% CD45 levels were protected from lethal EBOV challenge, with a survival rate of 90%-100%. In contrast, the CD45 100% , CD45 0% , CSV10 +/À , and CSV10 +/+ mice did not survive EBOV challenge ( Figure 1B ).
However, a delay in the mean time to death was observed in CD45 0% and CSV10 (+/À and +/+) mice.
Functional Consequences of Reduced CD45 Expression
To investigate whether reduced CD45 expression affects the entry, replication, or budding of the virus, splenocytes harvested from CD45
100%
, CD45 62% and CD45P 0% mice were infected ex vivo with EBOV, and viral titers were measured by plaque assay. As shown in Figure 1C , similar viral titers were obtained from splenocytes expressing different levels of CD45. Thus, changes in CD45 expression levels had no effect on viral replication.
The control and clearance of EBOV infection has been shown to correlate with effective humoral and T-cell-mediated responses, as mice vaccinated with Ebola virus-like particles (VLPs) require both B cells and CD* + T cells for protection against mouse-adapted EBOV infection (Warfield et al., 2005) . Accordingly, mice that survived EBOV challenge developed EBOVspecific antibodies ( Figure 1D ), and upon rechallenge with EBOV, a 100% survival rate (20/20) was observed for mice expressing a range of reduced CD45 levels (data not shown). Furthermore, CD8 + T cell responses against defined EBOV, GP, NP, and VP40 epitopes were observed by day 7 post-EBOV infection (data not shown).
Protective Immunity in EBOV-Infected CD45 62% Mice To understand the role of reduced CD45 expression during EBOV infection, we performed a time course study to monitor functional and cellular changes at both the transcript and protein levels ( Figure 2A ). Chemo/cytokine analysis of blood plasma indicated that MCP-1, FGF, IFN-g, IL-4, IL-10, and IL-12 were induced upon viral infection (day 3 and/or 5) in both the CD45 62% and CD45 100% mice ( Figure 2B ). A significant decrease (p < 0.05) in IL-4 levels was observed 3 days after infection in CD45 62% mice versus CD45 100% mice, and the levels of this cytokine were abolished by day 5 in both groups of mice. The levels of the regulatory cytokine IL-10 at day 3 were higher in CD45 100% compared to CD45 62% and completely abrogated by day 5 postinfection in CD45 100% mice. Thus, these data suggested that the initiation of optimal immunity in CD45 62% mice was achieved by regulated expression of IL-10 upon EBOV infection, which otherwise can suppress ongoing antiviral immunity (Couper et al., 2008 Figure 2C ). In blood, the percentage of activated CD8 + CD44 high+ T cells increased dramatically (p < 0.05) at 5 days after challenge in CD45 62% mice when compared to CD45 100% mice ( Figure 2D ). The CD45 62% mice had constitutively elevated percentages of activated T cells, and these increased levels were maintained through day 5 in both spleen and blood. a time course study showed that, at 7 days following EBOV challenge, the CD45 62% mice had reduced viral titers in the kidney, liver, spleen, and serum ( Figure 3A) . By day 10, no EBOV was detected in the different tissues of the CD45 62% mice, suggesting that a robust immune response was elicited in these mice ( Figure 3A) . Similarly, immunohistochemical staining of liver, spleen, and lymph nodes showed reduced EBOV antigen and increased cellularity of lymphocytes in the CD45 62% mice at 7 days following EBOV challenge ( Figure 3B ). No EBOV antigen was detected at 10 days ( Figure 3C ) or 30 days ( Figure 3D ) following EBOV challenge. Viral clearance was likewise observed in all other reduced-CD45-expressing mice that survived EBOV challenge (data not shown). In contrast, the CD45 100% mice failed to clear the virus and succumbed to the pathogen between 7 and 8 days following EBOV challenge. These studies indicated that the cellular integrity and observed active cellular homeostasis might have resulted in the viral clearance in CD45 62% mice.
EBOV infection is also associated with induced apoptosis of lymphocytes (Mohamadzadeh et al., 2007) . To detect apoptosis, we stained tissues from the time course study using the TUNEL technique. TUNEL staining of spleen samples from CD45 100% and CD45 62% mice on day 5 ( Figure 3E ) following EBOV challenge revealed apoptotic cells in red pulp areas where extramedullary hematopoiesis (EMH) normally occurs. In the EMH regions, significant cell depletion was observed on day 5 following infection in both groups of mice, suggesting prior loss or migration of cells. In the liver at day 5, there was no significant apoptosis observed in either group of mice ( Figure 3F ). However, by day 7, markedly increased (38-fold change compared to day 5) apoptosis was seen in the liver of CD45 100% mice. In contrast, there was much less apoptosis in the CD45 62% at day 7 in both the liver and spleen. These findings were confirmed by analyzing apoptosis characterized by the presence of pyknotic nuclei using H&E staining (data not shown) and by quantitation of the TUNEL-positive cells from the immunohistochemical images ( Figure 3G ). These data suggested that reduced CD45 expression levels may regulate EBOVinduced apoptosis of these cells.
Critical Role of CD8 + T Cells in Protecting CD45 62% Mice against EBOV Challenge Two independent approaches were taken to identify the critical cellular players responsible for the protective response in the CD45 62% mice. In one approach, Rag knockout mice expressing 62% or 100% CD45 levels were challenged with EBOV. Neither group of mice survived EBOV challenge, suggesting that B and/ or T cells are required for the mice to survive EBOV infection ( Figure 4A ). In the second approach, lymphocyte subsets were depleted in vivo using cell-type-specific antibodies prior to EBOV infection. As shown in Figure 4B , depletion of all T cells , or CSV10 (+/+, 100%) or CSV10 (+/À, 62%) mice having inactivated CD45 phosphatase activity did not survive EBOV infection. (C) Splenocytes harvested from 100%, 62%, and 0% CD45-expressing mice were infected (MOI = 1) ex vivo with mouse-adapted EBOV. At times 6, 24, 48, and 72 hr, supernatant was harvested and viral titers were determined by traditional plaque assays (Moe et al., 1981) . (D) Mice with reduced CD45 expression that survived EBOV challenge generated serum-EBOV-specific antibody responses. using CD90.2 (a Thy1.2 antibody) or depletion of CD8+ T cells resulted in increased mortality of the CD45 62% mice to EBOV challenge. In contrast, minimal susceptibility was observed following CD4+ T cell depletion, whereas depletion of NK subsets with NK1.1 antibody or treatment with IgG 2 b control antibody had no effect on mice survival. Activated CD8 + T cells secrete interferon g (IFN-g) to modulate immune function. To determine whether IFN-g played a role in protection of CD45 62% mice from EBOV infection, a neutralizing IFN-g antibody was used. Depletion of IFN-g resulted in susceptibility of CD45 62% mice to EBOV infection ( Figure 4C ), suggesting that this cytokine played a critical role in induced T cell immune responses against EBOV in CD45 62% mice. Together, these studies suggested that CD8 + T cells and IFN-g play a pivotal role in controlling infection in the CD45 62% mice.
Early Control of Gene Regulation in EBOV-Infected CD45 62% Mice To gain insight into the changes in gene regulation elicited upon EBOV infection, we used Affymetrix gene chip arrays to compare gene expression in splenocytes from CD45 100% and CD45 62% mice. Based on gene expression patterns, the variable genes were grouped into 16 clusters ( Figure 5A ). The clusters contained genes associated with cellular immune processes, signaling, cell-cycle, complement coagulation cascade, biosynthesis/ metabolism, ubiquitous genes involved in several cascades, and genes of unknown function (Table S1 available online) . Interestingly, gene expression at day 1 following EBOV challenge in CD45 100% mice was more similar to day 3 postinfection than preinfection. In contrast, at day 1 following EBOV infection, the CD45 62% mice maintained gene expression patterns similar to day 0. The differences in gene expression patterns between the CD45 100% and CD45 62% splenocytes were less apparent at day 3 following infection, and by days 5 and 7, they became very similar. At day 9, when wild-type mice had succumbed to the disease, the pattern in CD45 62% mice remained similar to the day 7 patterns of CD45 100% and CD45 62% mice. The pattern at days 11 and 13 in the CD45 62% mice became similar to that of day 0 CD45 100% or CD45 62% mice. These results suggested that, in CD45 100% mice, subversion of the cell transcriptional machinery during the early stages of EBOV infection (day 1) might represent a major factor leading to death of the mice. In Functional and Canonical Pathways Modulated by EBOV-Infected CD45 62% Mice To gain further insight into the changes in gene regulation upon EBOV infection, we examined Gene Ontology (GO) Biological Process annotations for genes that were significantly different between CD45
100% and CD45 62% mice at each time point (posterior probability of no change, p < 1E À 10 using the empirical Bayes; Kendziorski et al., 2003) . The primary biological functions that were significantly enriched (p < 0.05 by Fisher's exact test) among genes differentially expressed between the CD45 100% and CD45 62% (p < 1E À 10) over the course of EBOV infection included immune and inflammatory responses, chemotaxis, cell cycle, apoptosis, and antiapoptosis (Table 2) . In particular, the number of differentially expressed genes (A) Single cells were derived from kidney, liver, spleen, and serum of the EBOV-infected CD45 100% and CD45 62% mice on days 1, 3, 5, 7, 10, 16, and 21. Viral titers were measured using plaque assays (Moe et al., 1981) . The data represent averages of four mice per group per time point ± SD. (B) Immunohistochemical images of liver, spleen, and mesenteric lymph node from CD45 100% and CD45 62% mice euthanized at 7 days after EBOV infection and stained with anti-EBOV antibody. Scale bar, 100 um; 203 magnification. (C) CD45 62% mice euthanized at 10 days after EBOV infection and stained with anti-EBOV antibody. Scale bar, 100 um; 203 magnification.
(D) CD45 62% mice euthanized at 30 days after EBOV infection and stained with anti-EBOV antibody. Scale bar, 100 um; 203 magnification.
(E) TUNEL staining of spleen from CD45 100% and CD45 62% mice euthanized at 5 and 7 days after EBOV challenge. Scale bar, 100 mm; 203 magnification.
(F) TUNEL staining of liver from CD45 100% and CD45 62% mice euthanized at 5 and 7 days after EBOV challenge. Scale bar, 100 mm; 203 magnification.
(G) For quantitation of TUNEL staining, we acquired histology images as three separate black and white photos taken successively with a blue, green, and red filter on a Nikon E800 microscope with a SPOT RT camera. The color overlay function of MetaMorph imaging software (Molecular Devices Corporation, Downingtown, PA) was used to recombine the separate black and white images into a color image. To quantitate the number of apoptotic cells, black and white images taken with a green filter were each adjusted to an identical threshold value. The MetaMorph software ''count cells'' application was used to enumerate TUNELpositive cells.
associated with immune and inflammatory responses and chemotaxis were high on day 0 (before challenge) and day 5 following EBOV infection. Cell-cycle genes were significantly (p = 3.0E À 04) enriched at day 1, whereas an increased number of apoptotic and antiapoptotic genes were observed late in the infection process (day 7). This gene expression data supported our tissue pathology observations that indicated increased homeostasis and cellularity, as well as a concomitant increase in apoptosis on day 5 and a decreased apoptosis on day 7 in the CD45 62% mice during the middle to late stages of EBOV infection. Additionally, the expression results were analyzed using the Ingenuity Pathway Analysis software (Ingenuity Systems, http:// www.ingenuity.com). Ingenuity-defined canonical signaling pathways that were overrepresented (Fisher's exact test) among genes that differed between the CD45 62% and CD45 100% mice at day 1 after infection included IL-10 signaling, LXR/RXR activation, p53 signaling, and cell-cycle regulation pathways (Figure 5B) . Of great interest was the IL-10 signaling pathway, as increased levels of this cytokine have previously been reported in EBOV-infected humans during the first few days of clinical illness. However, they all succumbed to the lethal infection (Hutchinson and Rollin, 2007; Villinger et al., 1999) . Our array data showed reduced IL-10 expression throughout the course of EBOV infection in the CD45 62% mice when compared to CD45 100% mice ( Figure 5C ). A statistically significant reduction in IL-10 expression was observed only at days 3 (p = 7.8E À 5 by empirical Bayes; Kendziorski et al., 2003) and 7 (p = 0.029) following EBOV infection. However, a significant fraction of the genes within the IL-10-signaling pathway exhibited altered expression levels in the CD45 62% mice at day 1 (p = 6.0E À 4 by Fisher's exact test; Figure 6A ). Gene array analysis thus suggests that reduced CD45 levels may, in part, regulate immune mechanisms via IL-10 signaling, which is important for regulating or suppressing T cell responses.
DISCUSSION
In this study, we show that a range of reduced CD45 expression levels (11%-77%) resulted in a protective effect that allowed mice to survive EBOV infection. Furthermore, this effect was shown to be dependent on CD45 phosphatase activity, as mice with reduced expression levels of phosphatase-inactive CD45 succumb to the pathogen. CD45 62% mice demonstrated reduced viral titers in the kidney, liver, spleen, and serum 7 days following EBOV challenge, with no EBOV detected by day 10, suggesting that an unusually robust immune response elicited in CD45 62% mice might have allowed them to control the viral infection and subsequently survive EBOV challenge. Furthermore, significantly less cellular apoptosis was observed in both the livers and spleens of these mice relative to CD45 (Bradfute et al., 2008) . Our data indicated that CD8 + T cells and IFN-g are critical players in clearing EBOV infection in CD45 62% mice. We observed that CD45 62% mice had constitutively elevated percentages of activated T cells and macrophages and that these increased levels were maintained through day 5 in both the spleen and blood. In addition, our analysis suggested that intermediate CD45 levels might have controlled the inflammatory mechanisms by way of lowered IL-10 expression, which would lead to a heightened T cell response. Furthermore, depletion of all T cells, CD8 + T cells, or IFN-g (a product of CD8 + T cells) increased mortality of CD45 62% mice following EBOV challenge. It is known that a CD8 + T cell immune response is generated even during lethal EBOV infections, and adoptive transfer of these cells protects naive mice from EBOV challenge (Bradfute et al., 2008) . Our studies are consistent with a model in which the function and development of EBOV-specific CD8 + T cells is accelerated in the CD45 62% mice. Exactly how CD45 62% mice generate this unusually rapid/ robust immune response is uncertain. However, our microarray analysis suggests that CD45 62% mice were able to bypass the dramatic downregulation of gene expression elicited in CD45 100% mice following EBOV challenge. Specifically, gene expression in clusters 2 and 3 was observed to be downregulated on day 1 following EBOV challenge in CD45 100% mice. In contrast, on day 1 following EBOV infection, CD45 62% mice maintained gene expression patterns similar to those observed on day 0. These results indicated that lower expression levels of CD45 prevented EBOV subversion of the cell transcriptional machinery during the early stages of infection, suggesting that failure to control transcriptional regulation may represent a major factor leading to death in CD45 100% mice. These findings could be the basis for future studies to determine whether CD45 may play a controlling role in the wide variety of outcomes of Ebola virus infection, such as the resistance of mice to natural filovirus isolates. In addition to the observed increased number of CD8 + T cells in CD45 62% mice, our gene expression analysis indicated that increased trans-endothelial migration of effector CD8 + T cells to sites of viral infection might be influenced by CD45 levels. 3, 5, 7, 9, 11, and 13 (d0, d1, d3, d5, d7, d9, d11, and d13) post-EBOV infection. The heat map is of logB 2B expression values in splenocytes for 227 genes with coefficient of variation > 1.4. Genes and samples are arranged by dendrograms created with agglomerative nesting, and genes are assigned to 16 main clusters (colored bars). Clusters smaller than three genes are not numbered (white bars ). P values represent posterior probability of no change by empirical Bayes. The statistically significant p values are shown with an asterisk (*).
T cell migration is regulated by differential expression of various adhesion molecules and chemokines (Thomsen et al., 2003) . In our study, EBOV infection did not modulate the gene expression of integrin family members or selectins in either the CD45 100% or CD45 62% mice (data not shown). However, expression of intracellular adhesion molecule 4 (ICAM4) was significantly higher in CD45 62% compared to CD45 100% at days 1 (p = 3.7E À 08), 3 (p = 1.0E À 23), and 5 (p = 1.3E À 07) following EBOV challenge, which may have reduced or delayed T cell activation and differentiation ( Figure 6B ). In contrast, the vascular cell adhesion molecule-1 (VCAM-1) expression was lower in CD45 62% at days 1 and 5 following EBOV infection than in CD45 100% mice.
Furthermore, CD45 62% mice had significantly reduced expression of chemokine receptors, including CCR1 (days 0 and 1), CCR3 (days 0, 1, and 3), CXCL1 (days 0 and 1), and CXCL3 (days 0, 1, 5, and 7), following EBOV challenge ( Figure 6B ). In contrast, expression of CXCR3 was significantly higher (p = 7.5E À 04) at day 0 in CD45 62% mice but declined to that of CD45 100% mice on days 1, 3, 5, and 7 following EBOV infection. Thus, a balance between the expression levels of the appropriate adhesion molecules and chemokines may critically regulate lymphocyte migration to the site of infection and thereby influence the efficiency of the antiviral response in CD45 62% mice. How CD45 expression levels influence the antiviral response and its underlying molecular mechanism is unclear. Depending on the stimulus and the cell type, the role of CD45 in signal transduction varies. For example, the role of CD45 in regulating activation of Src family kinases, such as p56/59 hck and p53/56 lyn in macrophages, is distinct from its role in regulating the leukocytespecific protein tyrosine kinase p56 lck during lymphocyte antigen receptor signaling. Recently, McNeill et al. (McNeill et al., 2007) showed that differential CD45 expression levels appear to control the sensitivity of T cell signaling. Wild-type expression levels of a single CD45RO isoform were critical for dephosphorylation of pTyr394 of p56 lck , whereas intermediate levels of the CD45RO isoform were effective at dephosphorylating the pTyr-505 of p56 lck . In our study, the observed protective immunity elicited by intermediate CD45 levels may be a consequence of differential regulation of phosphorylation (at pTyr-505 and pTyr-394) of p56 lck (McNeill et al., 2007; Zamoyska, 2007) .
In vitro and in vivo mechanistic studies that monitor changes in the sensitivity of Src signaling in different cell types before and after EBOV infection, although technically challenging, would be the key to understanding how differential CD45 levels regulate innate and adaptive immune responses. The activities of virus-induced cellular mediators, including IFNs, cytokines, and intracellular signaling molecules, are controlled at multiple levels to provide an effective antiviral state. Based on our results, we propose a model wherein reduced CD45 expression regulates multiple mechanisms at different stages of EBOV infection ( Figure 6C ). Our studies suggest that homeostatic immune cell proliferation, enhanced cell trafficking and migration, regulated inflammation, and early control of gene expression related to disease pathogenesis collectively may contribute to reduced apoptosis, viral clearance, and survival of the EBOV-infected CD45 62% mice. Furthermore, the timing, location, interaction with binding partners, and signal intensity of the cellular, molecular, and immune responses all act in concert with the development of the host protective regulatory response in the CD45 62% mice challenged with EBOV.
Previously, we showed that intermediate levels of CD45 expression reduced apoptosis of B. anthracis-infected macrophages and protected mice from anthrax pathogenesis (Panchal et al., 2009) . Mechanism-based studies suggested that the protection provided by reduced CD45 levels resulted from regulated immune cell homeostasis that might have diminished the impact of apoptosis during the infection. Thus, in both the Ebola and B. anthracis infection models, reduced CD45 expression seems to regulate apoptosis by way of immune function. Although it is presumed that diverse pathogens elicit divergent molecular and cellular responses in mammalian hosts, these studies suggest that these phylogenetically distant pathogens likely converge at a singular, CD45-mediated process. However, whether or not similar gene regulatory events and/or signaling pathways are influenced by reduced CD45 expression in these distinct infection models remains to be investigated.
The similar ability of reduced CD45 levels to confer resistance to these two dissimilar pathogens may prove to be of extraordinary importance, as it highlights CD45 as a primary target for rational drug design. The therapeutic benefits of totally eliminating CD45 protein expression have been shown in Coxsackie B3 viral infections that cause severe immunopathologies (IrieSasaki et al., 2001) , whereas anti-CD45RO antibodies suppress the replication of human immunodeficiency virus in cultured human microglial cells (Kim et al., 2006) . On the contrary, our Enrichment of selected GO Biological Process annotations among genes differentially expressed between CD45 100% and CD45 62% mice (p < 1E À 10).
The number of genes, with indicated GO annotations, and one-tailed Fisher's exact p value for overrepresentation within the set of differentially expressed genes are shown for each time point. a p < 0.05.
studies show that reduced expression, but not complete knockout, of CD45 is critical for the protective phenotype following either EBOV or B. anthracis infection. The availability of a mouse model expressing differential levels of CD45 (Virts et al., 2003; Wallace et al., 1997) would allow us to further explore the effects and role of altered CD45 levels in these infectious disease models. Furthermore, therapeutic targeting of the downstream effector molecules of CD45 in combination with CD45 itself may prove beneficial for the development of host-based therapeutics. Importantly, the functional studies described here provide evidence that this enzyme is a promising target for host-based therapeutics for the treatment of a broad range of infectious diseases.
EXPERIMENTAL PROCEDURES
Transgenic and Heterozygous Mice All mice in this study are of the C57BL/6 genetic background. The heterozygous CD45 62% mice have one exon-9 knockout allele and one wild-type allele.
The CD45 transgenic mice were produced using a CD45 minigene construct containing cDNA from exons 1b-3, the genomic sequence from exon 3 to 9 (which includes the variably spliced exons and surrounding introns), and cDNA from exon 9 through the polyadenylation signal region in exon 33, as described previously (Virts et al., 2003; Virts and Raschke, 2001) . Three founder transgenic mice were obtained (B, F, and H), and each was bred to the exon-9 disrupted CD45 knockout strain (Byth et al., 1996) (obtained from Jackson Labs, Bar Harbor, ME). The properties of the F strain have been reported by Virts et al. (Virts et al., 2003) and include the same regulated, celltype-specific CD45 isoform expression as observed in wild-type mice. Transgenic mice containing a point mutation (C817S) in the membrane-proximal phosphatase domain of the CD45 minigene were also produced. This mutation has been shown to abolish CD45 PTPase activity in vitro (Desai et al., 1994) , and this has been confirmed in ex vivo studies (W.C.R. et al., unpublished data). The CSV10 transgenic mice were generated using the C817S mutant minigene, and the transgene locus was bred onto the CD45 knockout background. A more complete description of the properties of all transgenic strains in the knockout background, including those that express an inactive CD45 protein, will be published elsewhere (W.C.R. et al., unpublished data). The cell-surface expression levels of CD45 in all of the knockdown mice were determined using flow cytometry by comparison of the mean fluorescence intensities of the lymphocyte populations to those of CD45 100% wild-type and CD45 0% knockout mice (Virts et al., 2003 
Animal Studies
Mice (8-to 10-week-old) were used in this study and included both males and females. For in vivo Ebola studies, mice were challenged via intraperitoneal (i.p.) route with 1000 pfu of mouse-adapted Ebola Zaire virus. Mice that survived EBOV challenge were either rechallenged or they had their blood collected to measure anti-EBOV antibody levels in the serum by ELISA, and their tissues were harvested for pathology, T cell responses, and viral titer measurements (Warfield et al., 2006) . All research was conducted under an approved protocol and in compliance with the Animal Welfare Act, as well as other federal statutes and regulations related to animals and experiments involving animals, and adhered to principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council 1996. The facility where this research was conducted is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.
Flow Cytometry
Antibodies used for FACS analysis were purchased from BD PharMingen (San Diego, CA) unless otherwise noted. Antibodies used were directly conjugated to FITC, PE, APC, PerCP, or PECy5. Clones used in these studies included CD45 (30-F11), CD3 (17A2), CD4 (RM4-5), CD8 (53-6.7), CD11b (M1/70), CD11c (N418, eBioscience), CD19 (1D3), NK1.1 (PK136, eBioscience), MHC I (28-14-8), MHC II (M5/114.15.2), CD44 (IM7), and Ly6G (1A8). Cells (1 3 10 6 ) were resuspended in Fc block (anti CD16/CD32 antibody diluted in RPMI medium containing 10% FBS), incubated on ice for 30 min, centrifuged, and stained with appropriate combinations of labeled antibodies. After incubation on ice for 60 min, cells were washed and resuspended in 10% formaldehyde. FACS analysis was performed using a FACSCalibur flow cytometer (BD Biosciences). Data were analyzed using FlowJo software. Statistical analyses of the data were performed using the two-tailed Student's t test.
Cytokine Detection
Plasma separated from heparinized blood was analyzed for secreted cytokines using the mouse cytokine 20-plex AB Bead kit (Biosource). All analyses were performed on a Bio-Plex workstation using accompanying software (BioRad). Statistical analysis of the data was performed using the two-tailed Student's t test.
Ex Vivo Viral Replication CD45 100% , CD45
62%
, or CD45 0% mouse splenocytes (1 3 10 6 cells/ml) were infected with a multiplicity of infection of 0.1 of mouse-adapted Ebola virus. Cell-free supernatants were harvested at 6, 24, 48, or 72 hr and were then subjected to traditional plaque assay for determination of viral titers.
Immunohistochemical Staining
To detect the presence of EBOV in infected organs, the tissue sections were deparaffinized, blocked in methanol-HB 2B OB 2B solution for 30 min at room temperature (RT), rinsed with water, and pretreated with freshly diluted Proteinase K solution (20 mg/ml) for 15 min at RT. After blocking with the CAS block containing 5% goat serum, the sections were incubated with Rabbit anti-Ebola (994) antibody for 60 min at RT. After rinsing three times with PBS, peroxidase-labeled polymer conjugated to goat anti-rabbit immunoglobulins was added and incubated for 30 min. After rinsing with PBS, substrate-chromogen solution was added, incubated for 5 min, rinsed with PBS, stained with hematoxylin, and dehydrated, and tissues were mounted with Permount. Apoptosis in tissues was detected by the TUNEL method using the Apoptag Plus peroxidase in situ apoptosis kit (Chemicon). Processing of the tissue samples was carried out as described above, with the following changes. After proteinase K treatment and washing, tissues were incubated with terminal deoxynucleotidyl transferase (TdT) for 60 min at 37 C. The reaction was stopped by adding stop/wash buffer and incubating for 10 min at RT. After washing three times with PBS, the tissues were incubated with anti-digoxigenin-peroxidase for 30 min at RT. Color development was visualized using the DAB substrate. Slides were counterstained with methyl green.
In Vivo Antibody Depletion Lymphocyte subsets were depleted as described previously (Alici et al., 2007; King et al., 2008; Wang et al., 2003; Yang et al., 2006) by i.p. injection of 300 mg of functional grade antibodies on days À3, À1, and +3. Antibodies used to deplete lymphocyte subsets were NK1.1 (clone PK136), CD4 (clone GK1.5), CD8 (clone 53-6.7), CD90.2 (clone 30-H12), and a rat IgG1 isotype control, all purchased from eBioscience (San Diego, CA). For the in vivo IFN-g studies, 300 mg of functional grade anti-IFN-g antibody (clone XMG1.2) or a rat IgG1 isotype control was injected i.p. on days À1, +1, +3, +6, and +11, similar to previously reported methods (Zhong et al., 2001 ).
Gene Expression Studies and Microarray Analysis
Splenocytes isolated from spleen of wild-type (100%) and/or heterozygous (62%) mice at days 0, 1, 3, 5, 7, 9, 11, and 13 were resuspended in 2 ml TRIzol solution. The samples were stored at À70 C until the RNA was purified. Total cellular RNA was isolated as per the manufacturer's specifications. The quality and concentration of the RNA were determined by measuring the absorbance at 260 and 280 nm. RNA integrity was confirmed using an Agilent 2100 Bioanalyzer (Agilent technologies, Palo Alto, CA). The mouse genome 430 2.0 array (Affymetrix, Inc.), which consists of more than 39,000 genes in a single array, was used. Affymetrix CEL files were preprocessed using GCRMA (version 2.12.1) (Wu et al., 2004) in R/Bioconductor (http://www.bioconductor.org). Median log 2 expression values within each sample type/time point with a coefficient of variation (CV) > 1.4 were chosen using the Bioconductor package genefilter for agglomerative hierarchical clustering. Affymetrix control probesets, Xist, and genes on the Y chromosome were removed, and the probeset with the largest CV was chosen for genes with > 1 probeset. Cluster stability was assessed using the Bioconductor package clusterStab to suggest cluster boundaries. The probeset with the largest CV for each Entrez identifier was chosen for upload of median log 2 (CD45 62% /CD45 100% ratios) and EBarrays probabilities to Ingenuity Pathways Analysis version 6.3 (Ingenuity Systems, http://www.ingenuity.com). GO term enrichment was determined with the Bioconductor package GOstats (version 2.6.0) (Falcon and Gentleman, 2007) with annotation information from GO.db. Analyses were performed with a significance cutoff that posterior probability of no change < 1E À 10.
ACCESSION NUMBERS
Microarray data are available online at the Gene Expression Omnibus website (http://www.ncbi.nlm.nih.gov/geo), accession number XXX.
SUPPLEMENTAL DATA
Supplemental Data include one table and can be found with this article online at http://www.cell.com/cell-host-microbe/supplemental/S1931-3128(09)00248-0.
